NMR dynamics and antibody recognition of the meningococcal lipidated outer membrane protein LP2086 in micellar

Alessandro Mascioni1, Franklin J Moy, Lisa K McNeil

  • 1Wyeth Research, Structural Biology and Computational Chemistry, 200 Cambridge Park Drive, Cambridge, MA 02140, USA.

Insights

Outer membrane protein LP2086-B01 from Neisseria meningitidis is key for vaccines. Its flexible structure enhances immune system access to critical antigen domains, improving vaccine potential against meningitis B.

Area of Science:

  • Microbiology
  • Structural Biology
  • Immunology

Background:

  • Neisseria meningitidis serogroup B poses a significant challenge for meningitis vaccines.
  • Outer membrane lipoprotein LP2086 (factor H binding protein, fHbp) is a promising vaccine antigen.
  • Previous studies proposed a model where LP2086's flexible linker enhances antigen exposure.

Purpose of the Study:

  • To investigate the backbone dynamics of LP2086-B01 in lipidated and unlipidated forms.
  • To characterize the interaction of LP2086-B01 with monoclonal antibody MN86-1042-2.
  • To validate the proposed topology and antigen accessibility model of LP2086-B01.

Main Methods:

  • Nuclear Magnetic Resonance (NMR) spectroscopy to determine backbone dynamics in micellar solutions.
  • Flow cytometry on whole meningococcal cells.
  • Binding experiments using monoclonal antibody fragments (Fab).

Main Results:

  • The N-terminal linker's flexibility prevents antigen contact with the bacterial membrane, ensuring domain availability.
  • Both N- and C-domains of LP2086-B01 are highly accessible to the host immune system.
  • The N-domain is the primary target for the MN86-1042-2 antibody, confirming its immunological importance.

Conclusions:

  • LP2086-B01 exhibits a dynamic structure that optimizes antigen exposure for immune recognition.
  • The proposed model of LP2086-B01 topology is supported, highlighting the N-domain's immunogenicity.
  • These findings reinforce LP2086 as a critical target for developing effective vaccines against Neisseria meningitidis serogroup B.

Related Concept Videos